-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Mucopolysaccharidosis III (MPS III)...
-
Product Insights
NewNet Present Value Model: Nippon Shinyaku Co Ltd’s CAP-1002
Empower your strategies with our Net Present Value Model: Nippon Shinyaku Co Ltd's CAP-1002 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pulmonary Sarcoidosis Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pyoderma Gangrenosum
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pyoderma Gangrenosum report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pyoderma Gangrenosum Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Sickle Cell Disease Drug Details: Canakinumab (Ilaris / Lasprona...
-
Sector Analysis
Greece Cards and Payments – Opportunities and Risks to 2027
Greece Cards and Payments Market Report Overview The annual value of card transactions in the Greece cards and payments market was $76.9 billion in 2023. The value is expected to grow at a CAGR of more than 7% during 2023-2027. Cash is the preferred payment method in Greece. However, the government has undertaken various initiatives to boost electronic payments in the country, such as a cap on cash transactions and electronic payment of salaries. Greek consumers are substituting cash payments...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tozorakimab in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tozorakimab in Asthma Drug Details: Tozorakimab (MEDI-3506) is under development for the treatment...
-
Product Insights
Cap Des Biches Gas Fired Combined Cycle Power Plant
Cap Des Biches Gas Fired Combined Cycle Power Plant is a thermal project located in Dakar, Senegal. The project is owned by Senegal National Electricity Agency; West African Energy SA and is developed by West African Energy SA. The project is currently under construction. Empower your strategies with our Cap Des Biches Gas Fired Combined Cycle Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will...
-
Product Insights
A3 Capital / Gaw Cap – Cyberjaya Data Centre – Kuala Lumpur
The A3 Capital / Gaw Cap – Cyberjaya Data Centre – Kuala Lumpur project involves the construction of a 17,000m2, seven-story data center comprising 1,830 cabinets with a capacity of 12MW in Cyberjaya, Selangor, Malaysia. Equip yourself with the essential tools needed to make informed and profitable decisions with our A3 Capital / Gaw Cap – Cyberjaya Data Centre – Kuala Lumpur report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered...
-
Company Insights
Innovation and Patenting activity of CAP SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CAP SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...